Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a common ED drug reduce birth emergencies?

NCT ID NCT06522854

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This pilot study aimed to see if giving sildenafil (the drug in Viagra) to women in labor could prevent fetal distress, reduce the need for emergency C-sections or forceps deliveries, and lower the risk of newborns needing breathing help. The trial planned to enroll 120 women in low-resource countries, comparing sildenafil to a placebo. However, the study was withdrawn before any participants were enrolled, so no conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sildenafil citrate (oral tablet, 50 mg)
What this could lead to
If this pilot works, it could point toward a simple, low-cost way to reduce emergency C-sections and newborn breathing problems in low-resource settings.
What could go wrong
This trial was withdrawn before enrolling anyone, so no results exist. Even if run later, it is a small feasibility study, not proof of benefit. Sildenafil can cause side effects like headache or low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Expected to start

May 2025

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 days to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Pregnant women presenting in early labor with a term pregnancy (≥ 37 weeks to 41wks 6days gestation ) * Early labor will be defined as cervical dilation less than 7cm * Gestational age will be calculated from the most reliable variable using the following hierarchy of reliability: 2) gestational dating ultrasound completed at any time during the pregnancy (with preference to the earliest exam); 2) date of last menstrual period if menses are regular. 2. Planned vaginal delivery and admission to health facility with clear plan for spontaneous or induced vaginal delivery 3. Maternal age ≥ 18yrs Exclusion Criteria: 1. Unknown gestational age 2. Non-cephalic fetal presentation 3. Plan for cesarean delivery prior to enrollment 4. Previous uterine scar (cesarean section and/or myomectomy) 5. Advanced stage of labor (7 cm or greater cervical dilation per local standards) and pushing, or too distressed to understand, confirm, or give informed consent regardless of cervical dilation 6. Not capable of giving consent due to other health problems, such as obstetric emergencies (i.e. antepartum hemorrhage) or mental disorder 7. Maternal contraindication to sildenafil therapy, such as hypersensitivity to nitrates or nitrites 8. Recognized major structural fetal anomaly 9. Previous randomization in the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Instrumental delivery; affecting fetus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ladoke Akintola University of Technology Teaching Hospital

    Ogbomoso, Oyo State, 210271, Nigeria

  • Lagos Island Maternity Hospital

    Lagos, Lagos, 101001, Nigeria

  • Mother and Child Hospital

    Surulere, Lagos, 101241, Nigeria

  • University Teaching Hospital, University of Lagos

    Lagos, Lagos, 102215, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.